CD47 and malignant colon neoplasm: Anti-SIRPα antibody treatment leads to enhanced macrophage phagocytic activity (67) and reduced tumor progression in a mouse model of colon cancer (67) and CD47-SIRPα signaling promotes the expansion and metastasis of colon cancer cells in tumor microenvironments that are rich in tumor-associated macrophages (68).